Amgen

News

Viridian has fired a shot across Amgen's bows with the FDA approval of Tepezza rival Lumvoa in thyroid eye disease, a $2bn market.

News

Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the CHMP recommended its marketing authorisation by revoked in the EU.

News

The FDA has published a plan to allow data from clinical trials to be reported to the agency as they occur in real time.

News

In this week's second AI model launch for life sciences research, OpenAI has introduced GPT-Rosalind, named after UK scientist Rosalind Franklin.

News

Can Amgen's subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster?

News

The FDA has raised the pressure on Amgen to withdraw vasculitis drug Tavneos from the market with a report linking serious side effects to the drug.